CN117695351B - 一种治疗煤工尘肺的中药组合物及制备方法 - Google Patents
一种治疗煤工尘肺的中药组合物及制备方法 Download PDFInfo
- Publication number
- CN117695351B CN117695351B CN202311647320.1A CN202311647320A CN117695351B CN 117695351 B CN117695351 B CN 117695351B CN 202311647320 A CN202311647320 A CN 202311647320A CN 117695351 B CN117695351 B CN 117695351B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- coal dust
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 239000002817 coal dust Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 210000004072 lung Anatomy 0.000 claims abstract description 49
- 206010011224 Cough Diseases 0.000 claims abstract description 21
- 208000000059 Dyspnea Diseases 0.000 claims abstract description 18
- 206010013975 Dyspnoeas Diseases 0.000 claims abstract description 18
- 241000222336 Ganoderma Species 0.000 claims abstract description 10
- 239000009636 Huang Qi Substances 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 241000628997 Flos Species 0.000 claims abstract description 5
- 241000243684 Lumbricus Species 0.000 claims abstract description 5
- 206010036790 Productive cough Diseases 0.000 claims abstract description 5
- 235000006533 astragalus Nutrition 0.000 claims description 15
- 241001061264 Astragalus Species 0.000 claims description 13
- 210000004233 talus Anatomy 0.000 claims description 13
- 241000490229 Eucephalus Species 0.000 claims description 12
- 244000042430 Rhodiola rosea Species 0.000 claims description 12
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 12
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims description 12
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 12
- 241000361919 Metaphire sieboldi Species 0.000 claims description 11
- 241001369613 Stephania tetrandra Species 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 241001547125 Fritillaria thunbergii Species 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 206010035653 pneumoconiosis Diseases 0.000 claims description 8
- 241000125175 Angelica Species 0.000 claims description 7
- 240000008397 Ganoderma lucidum Species 0.000 claims description 7
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 241000935235 Fritillaria meleagris Species 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241000205585 Aquilegia canadensis Species 0.000 claims 6
- 241000213006 Angelica dahurica Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 208000024891 symptom Diseases 0.000 abstract description 19
- 210000004185 liver Anatomy 0.000 abstract description 7
- 206010067482 No adverse event Diseases 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000003907 kidney function Effects 0.000 abstract description 2
- 230000003908 liver function Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 24
- 238000011282 treatment Methods 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 206010062717 Increased upper airway secretion Diseases 0.000 description 21
- 208000026435 phlegm Diseases 0.000 description 21
- 230000007812 deficiency Effects 0.000 description 18
- 208000006673 asthma Diseases 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 241000382455 Angelica sinensis Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000428 dust Substances 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 241001570521 Lonicera periclymenum Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 5
- 239000003245 coal Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 235000019605 sweet taste sensations Nutrition 0.000 description 5
- 241001290772 Limnodrilus Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 229940107666 astragalus root Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000004199 lung function Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 244000167230 Lonicera japonica Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011272 standard treatment Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000132092 Aster Species 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000002300 anti-fibrosis Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229940121707 Calmodulin antagonist Drugs 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 241000243679 Lumbricidae Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 241000997135 Rhodiola crenulata Species 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 compound dextromethorphan hydrobromide Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中医药技术领域,具体涉及一种治疗煤工尘肺的中药组合物及制备方法。中药组合物的中药材原料由以下成分组成:生黄芪、金银花、当归、浙贝母、瓜蒌皮、紫菀、地龙、防己、红景天、灵芝。本发明还提出了中药组合物的制备方法。本发明的中药组合物用于治疗煤工尘肺引起的呼吸困难、咳嗽、咳痰症状。本发明的中药组合物临床疗效确切,能显著提高患者的生活质量,并且无肝肾功能损害等不良反应,服用、携带都很方便,患者依从性较好,且价格低廉,适合大规模使用。
Description
技术领域
本发明属于中医药技术领域,具体涉及一种治疗煤工尘肺的中药组合物及制备方法。
背景技术
煤工尘肺是由于在职业活动中长期吸入生产性粉尘并在肺内潴留而引起的以肺组织弥漫性纤维化为主的全身性疾病,煤工尘肺患者在我国是最多的,因其多暴露在含二氧化硅与煤尘的混合性粉尘中,故病情也较为严重,煤工尘肺后期往往发展成肺间质纤维化。对于煤工尘肺的治疗多以止咳化痰平喘为主,但目前还没有报道涉及益气活血、化痰通络的治疗原则。
发明内容
鉴于此,本发明依据病机,以益气活血、化痰通络为治疗原则,提供一种治疗煤工尘肺的中药组合物,所述中药组合物的中药材原料由以下成分组成:生黄芪、金银花、当归、浙贝母、瓜蒌皮、紫菀、地龙、防己、红景天、灵芝。
进一步可选地,所述中药材原料由以下重量比组成:生黄芪1-10份、金银花1-6份、当归1-6份、浙贝母1-4份、瓜蒌皮1-4份、紫菀1-4份、地龙1-3份、防己1-3份、红景天1-6份、灵芝1-6份。
进一步可选地,所述中药材原料由以下重量比组成:生黄芪4-8份、金银花3-6份、当归3-6份、浙贝母2-4份、瓜蒌皮2-4份、紫菀2-4份、地龙1-3份、防己1-3份、红景天3-6份、灵芝3-6份。
进一步可选地,所述中药材原料由以下重量比组成:生黄芪6份、金银花4份、当归4份、浙贝母2份、瓜蒌皮2份、紫菀2份、地龙2份、防己2份、红景天3份、灵芝3份。
进一步可选地,所述中药组合物是口服制剂,所述口服制剂为颗粒剂或汤剂。
进一步可选地,所述中药组合物为颗粒剂。
本发明提供一种上述中药组合物的制备方法,所述制备方法包括以下步骤:
按上述重量比称取各种中药材,并混合;
加入水煎煮若干次,合并各次水煎液;
过滤,浓缩,得浓缩液。
进一步可选地,所述制备方法还包括以下步骤:
将所述浓缩液进一步浓缩至清膏,加入辅料,干燥,将干燥后的物质进行制粒。
本发明提供一种上述中药组合物在制备治疗煤工尘肺药物中的应用。
进一步可选地,所述煤工尘肺的病症为:呼吸困难、咳嗽、咳痰。
本发明所用中药材的药用部位、性味归经、功效、作用如下:
生黄芪为豆科植物蒙古黄芪或膜荚黄芪的根。性微温,味甘,归脾、肺经。具有补气升阳、益卫固表、托毒生肌、利水退肿的功效。作用:①用于脾肺气虚或中气下陷之证;②用于卫气虚所致表虚自汗;③用于气血不足所致痈疽不溃或溃久不敛;④用于浮肿尿少;⑤用于气虚血滞导致的肢体麻木、关节痹痛或半身不遂,以及气虚津亏的消渴等证。
金银花为忍冬科植物忍冬的花蕾。性寒,味甘,归肺、心、胃经。具有清热解毒、疏散风热的功效。作用:①外感风热或温热病初起,发热而微恶寒者;②用于疮、痈、疖肿;③用于热毒泻痢、下痢脓血之证。
当归为伞形科植物当归的根。性温,味甘、辛,归肝、心、脾经。具有补血、活血、止痛、润肠的功效。作用:①用于血虚诸证;②用于月经不调、经闭、痛经;③用于虚寒腹痛、瘀血作痛、跌打损伤、痹痛麻木;④用于痈疽疮疡;⑤用于血虚肠燥便秘。
浙贝母为百合科植物浙贝母的鳞茎。性寒,味苦,归肺、心经。具有化痰止咳、清热散结的功效。作用:①用于肺虚久咳,痰少咽燥,以及外感风热咳嗽,或痰火郁结,咯痰黄稠等证。②用于瘰疬疮痈肿毒及乳痈、肺痈、甲状腺肿瘤等证。
瓜萎皮为葫芦科植物栝楼或双边栝楼等的果皮。性寒,味甘,归肺、胃经。具有润肺化痰、利气宽胸的功效。作用:用于痰热咳嗽、咽痛、胸痛、吐血、衄血、消渴、便秘、痈疮肿毒。
紫菀为菊科植物紫菀的干燥根和根茎。性温,味辛、苦,归肺经。具有润肺下气、化痰止咳的功效。作用:用于痰多喘咳、新久咳嗽、劳嗽咳血。
地龙为巨蚓科动物参环毛蚓和威廉环毛蚓、栉盲环毛蚓、通谷环毛蚓等的全体。性寒、味咸、归肝、脾、膀胱经。具有清热止痉、平肝熄风、通经活络、平喘利尿的功效。作用:用于热病发热狂燥、惊痫抽搐、肝阳头痛、中风偏瘫、风湿痹痛、肺热喘咳、小便不通。
防己为防己科植物粉防己的干燥根。性寒,味苦,归膀胱、肺经。具有祛风止痛、利水消肿的功效。作用:用于治疗风湿痹痛、水肿脚气、小便不利、湿疹疮毒等。现代研究表明汉防己甲素既是天然的非选择性钙通道阻滞药,又是钙调蛋白拮抗药,具有抗炎、抗纤维化等药理作用,临床用于治疗各期煤硅肺。
红景天为景天科植物大花红景天的干燥根和根茎。性平,味甘、苦,归肺、心经。具有益气活血、通脉平喘的功效。作用:用于气虚血瘀、胸痹心痛、中风偏瘫、倦怠气喘。
灵芝为多孔菌科真菌赤芝的干燥子实体。性平,味甘,归心、肺、肝、肾经。具有补气安神、止咳平喘的功效。作用:用于心神不宁、失眠心悸、肺虚咳喘、虚劳短气、不思饮食。
肺主气而开窍于鼻,为五脏六腑之华盖,外邪侵袭,首先犯肺。而煤工尘肺患者长期处于粉尘环境中,尘毒袭肺,患者反复感受毒邪,卫外防御功能减退,病程迁延不愈,损伤正气,久而致肺气亏虚。煤尘属于金石一类,其性燥烈,沉积于肺,燥伤肺津,致肺气阴两虚,气虚津液不能输布,阴虚生热炼液成痰,有害物质沉积不去,久则化热灼津为痰,痰热互结。煤尘蕴积于肺,既耗气伤阴,又阻塞肺络,阻遏气机,气血运行阻滞,血脉不通,进而导致气滞血瘀,故尘肺患者往往病程迁延,气阴两虚,气虚则运血无力,津血同源,阴虚津亏无以充血则血脉不利,均会进一步加重血瘀。
发明人在多年中医临床经验的基础上,总结出对煤工尘肺的诊疗规律以及经验用药,认为本病病机为气虛血瘀、痰瘀阻络,因此益气活血、化痰通络的治疗原则应贯穿于治疗煤工尘肺的全程。方中生黄芪为君药,生黄芪性微温,具有健脾补中、升阳举陷、益卫固表的功效,《本草求真》言:“黄芪,入肺补气,入表实卫,为补气诸药之最”。金银花、当归为臣药,金银花性寒,具有清热解毒、疏散风热的功效,生黄芪、金银花配伍,一热一凉,生黄芪大补元气,金银花辛凉透散,可佐制生黄芪之温性,两药配伍益气解毒、通利血脉;当归,性辛温,补血活血,为补血之圣药,气为血之帅,生黄芪补气行血,血为气之母,当归养血行气,二者配伍取自当归补血汤之意,既补气血,又通肺络,当归与金银花相配通利血脉,养不留滞,活血而不致血液妄行,现代药理研究表明生黄芪、当归皆可调节免疫功能,又可促进造血,有逆转肺、肝纤维化的作用。浙贝母、瓜蒌皮、紫菀、红景天、灵芝、地龙、防己均为佐使药,浙贝母、瓜萎皮性寒,皆具有清热化痰、行气散结的功效;紫菀,性温,止咳平喘,同时防止金银花、浙贝母、瓜蒌皮等过于苦寒;红景天、灵芝补肺益气,能提高机体耐缺氧能力,改善呼吸困难的症状;地龙通络平喘,与生黄芪配伍具有补气、活血、通络的功效;防己具有抗炎、抗纤维化等药理作用,临床常用于治疗各期煤硅肺。全方寒热并用,补中寓通,共凑益气解毒活血、清热化痰通络之功。
本发明通过对中药煎煮提取后,获取了中药方剂的活性成分,口服这些提取物后,能够治疗煤工尘肺。本领域技术人员根据常识可以理解,本发明实现治疗煤工尘肺最简单的实施方式,可以为对中药煎煮提取后,直接服用浓缩后的汤剂。为了减轻患者的服药困难,本领域技术人员可以根据常规的制剂技术,将中药提取的清膏与本领域常规辅料组合制备其他口服制剂,例如制成颗粒剂。例如将本发明浓缩得到的清膏制成颗粒剂,每日一剂,水冲服400ml,分早晚两次饭后温服,连续服用4周。
与现有技术相比本发明的有益效果为:
本发明的中药组合物能有效改善煤工尘肺患者的呼吸困难、咳嗽、咳痰等症状,临床疗效确切,能显著提高患者的生活质量,并且无肝肾功能损害等不良反应,服用、携带都很方便,患者依从性较好,且价格低廉,适合大规模使用。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式,熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
在本发明实施例中使用的术语是仅仅出于描述特定实施例的目的,而非旨在限制本发明。在本发明实施例和所附权利要求书中所使用的单数形式的“一种”、“所述”和“该”也旨在包括多数形式,除非上下文清楚地表示其他含义,“多种”一般包含至少两种,但是不排除包含至少一种的情况。
实施例1-6
按表1所示的重量称取各中药材。
表1实施例1-6中各中药材的重量
实施例7
实施例7为将实施例1的中药材制成颗粒剂,制备方法包括以下步骤:
分别称取生黄芪30g、金银花20g、当归20g、浙贝母10g、瓜蒌皮10g、紫菀10g、地龙10g、防己10g、红景天15g、灵芝15g,混合,加入水煎煮,合并水煎液,过滤,浓缩至清膏,加入辅料,干燥,再加入辅料,混匀,制粒,即得一剂中药组合物颗粒。
试验例
本试验例为将实施例7制得的中药组合物颗粒在治疗煤工尘肺临床上的研究。
在北京中医药大学房山医院随机选取80例煤工尘肺患者,随机分为试验组与对照组,每组40例,均为男性患者,试验组脱落2例(1例因病情急性加重,1例因未按计划治疗),对照组脱落1例(因失访)。如表2所示,试验组年龄53-77岁,平均年龄(63.97±5.66)岁;接尘时间9-40年,平均(22.82±8.08)年;尘肺分期:Ⅰ期26例、Ⅱ期11例、Ⅲ期1例。对照组年龄52-83岁,平均年龄(65.51±6.79)岁;接尘时间8-36年,平均(23.51±7.58)年;尘肺分期:Ⅰ期25例、Ⅱ期13例、Ⅲ期1例。两组患者的基本情况相比较,差异均无统计学意义(P>0.05),具有可比性,本研究经北京中医药大学房山医院伦理委员会批准。
表2试验组与对照组患者的基本情况
诊断标准:(1)西医诊断标准参照《职业性尘肺病的诊断》,根据可靠的生产性矿物性粉尘接触史,以技术质量合格的X射线高千伏或数字化摄影(DR)后前位胸片表现为主要依据,结合工作场所职业卫生学、尘肺流行学调查资料以及职业健康监护资料,参考临床表现以及实验室检查,排除其他类似肺部疾病后,对照尘肺诊断标准片来进行诊断。(2)中医诊断标准参照《中华人民共和国中医药行业标准一中医内科病证诊断疗效标准》中的“咳嗽”、“喘证”以及《实用中医内科学》中的“咳嗽”、“喘证”等诊断标准,总结文献资料,结合既往临床经验,制定出煤工尘肺患者的肺气亏虚、痰瘀阻络的诊断标准为:主症:①呼吸困难,②咳嗽,③咳痰;兼症:①喘息,②气短,③胸痛,④乏力,⑤便溏,⑥水肿,⑦口唇爪甲紫绀,⑧舌质淡暗、舌质暗红、舌体胖大等,⑨苔白或黄,⑩脉细、脉沉、脉涩等,主症必备,合并兼症中2项以上便可进行诊断。
纳入标准:①符合煤工尘肺Ⅰ、Ⅱ、Ⅲ期的诊断标准;②符合肺气亏虚、痰瘀阻络的诊断标准;③年龄大于或等于18周岁;④同意参加本试验并签署知情同意书。
排除标准:①合并有心血管、血液、肝、肾、神经系统等严重原发病;②合并精神类疾病;③过敏体质或对本试验服用药物过敏者。
治疗方案:试验组给予本发明实施例7制得的中药组合物颗粒+西医标准治疗;对照组给予中药组合物安慰剂+西医标准治疗。中药组合物颗粒:每日一剂,水冲服400ml,分早晚两次饭后温服;中药组合物安慰剂:5%中药组合物颗粒+95%糊精,安慰剂在形状、颜色、气味、质感等方面均与中药组合物颗粒类似,受试者难以区分。安慰剂每日一剂,水冲服400ml,分早晚两次饭后温服。西医标准治疗参照《尘肺病治疗中国专家共识》:①憋喘明显者使用布地奈德福莫特罗粉吸入剂,1-2吸/次,一日2次,或沙美特罗替卡松粉吸入剂,1吸/次,一日2次;②咳嗽明显者使用复方氢溴酸右美沙芬糖浆,10ml/次,一日3次;③痰多者使用盐酸氨溴索分散片,1-2片/次,一日3次,或羧甲司坦口服溶液,10ml/次,一日3次。试验组与对照组均连续治疗4周。
主要评价指标:将治疗呼吸困难的有效率作为主要评价指标,依据尼莫地平法,疗效指数n=[(治疗前积分-治疗后积分)÷治疗前积分]×100%,
临床控制:呼吸困难症状消失或基本消失,n≥95%;
显效:呼吸困难症状改善,95%>n≥70%;
有效:呼吸困难症状有好转,70%>n≥30%;
无效:呼吸困难症状不减轻或加重,n<30%,
治疗呼吸困难的有效率=(临床控制人数+显效人数+有效人数)/(临床控制人数+显效人数+有效人数+无效人数)*100%。
次要评价指标:
①中医症状积分表:对比两组治疗前后中医症状积分的差异;
②肺功能:对比两组治疗前后肺功能相关指标的差异;
③6分钟步行试验:对比两组治疗前后6分钟步行距离的差异。
安全性指标:治疗后血常规、尿常规、肝肾功能异常的发生率=治疗后指标异常人数/总人数。
试验组与对照组患者治疗呼吸困难的有效率见表3。
表3试验组与对照组患者治疗呼吸困难的有效率[例(%)]
注:与对照组相比,*P<0.05。
即在治疗4周后,试验组患者治疗呼吸困难的有效率要明显高于对照组。
试验组与对照组患者的中医症状积分见表4。
表4试验组与对照组患者的中医症状积分
注:与治疗前相比,△P<0.05;与对照组相比,*P<0.05。
即与治疗前以及与对照组相比,4周后试验组患者的中医症状积分均明显下降。
试验组与对照组患者的肺功能相关指标见表5。
表5试验组与对照组患者的肺功能相关指标
注:与治疗前相比,△P<0.05。
即与治疗前相比,4周后试验组患者的FVC指标明显改善。
试验组与对照组患者的6分钟步行距离见表6。
表6试验组与对照组患者的6分钟步行距离(m)
注:与治疗前相比,△P<0.05;与对照组相比,*P<0.05。
即与治疗前以及与对照组相比,4周后试验组患者的6分钟步行距离明显增加。
在治疗期间,试验组与对照组患者均未出现明显不适,且均未涉及任何安全性事件。
综上,经过4周的治疗,煤工尘肺患者的呼吸困难症状得到了有效的改善,同时患者的中医症状积分明显下降、肺功能指标明显改善、6分钟步行距离明显增加,并且在治疗期间试验组与对照组患者均未出现明显不适,因此本发明的中药组合物具有确切的临床疗效,能显著提高患者的生活质量。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种治疗煤工尘肺的中药组合物,其特征在于,所述中药组合物的中药材原料由以下成分组成:生黄芪、金银花、当归、浙贝母、瓜蒌皮、紫菀、地龙、防己、红景天、灵芝;
所述生黄芪、金银花、当归、浙贝母、瓜蒌皮、紫菀、地龙、防己、红景天、灵芝为以下重量比:生黄芪1-10份、金银花1-6份、当归1-6份、浙贝母1-4份、瓜蒌皮1-4份、紫菀1-4份、地龙1-3份、防己1-3份、红景天1-6份、灵芝1-6份。
2.根据权利要求1所述的治疗煤工尘肺的中药组合物,其特征在于,所述生黄芪、金银花、当归、浙贝母、瓜蒌皮、紫菀、地龙、防己、红景天、灵芝为以下重量比:生黄芪4-8份、金银花3-6份、当归3-6份、浙贝母2-4份、瓜蒌皮2-4份、紫菀2-4份、地龙1-3份、防己1-3份、红景天3-6份、灵芝3-6份。
3.根据权利要求2所述的治疗煤工尘肺的中药组合物,其特征在于,所述生黄芪、金银花、当归、浙贝母、瓜蒌皮、紫菀、地龙、防己、红景天、灵芝为以下重量比:生黄芪6份、金银花4份、当归4份、浙贝母2份、瓜蒌皮2份、紫菀2份、地龙2份、防己2份、红景天3份、灵芝3份。
4.根据权利要求1-3任意一项所述的中药组合物,其特征在于,所述中药组合物是口服制剂,所述口服制剂为颗粒剂或汤剂。
5.根据权利要求4所述的中药组合物,其特征在于,所述中药组合物为颗粒剂。
6.一种权利要求1-4任意一项所述的中药组合物的制备方法,其特征在于,所述制备方法包括以下步骤:
按权利要求1-4任意一项所述的中药组合物的重量比称取各种中药材,并混合;
加入水煎煮若干次,合并各次水煎液;
过滤,浓缩,得浓缩液。
7.根据权利要求6所述的制备方法,其特征在于,所述制备方法还包括以下步骤:
将所述浓缩液进一步浓缩至清膏,加入辅料,干燥,将干燥后的物质进行制粒。
8.一种权利要求1-5任意一项所述的中药组合物在制备治疗煤工尘肺药物中的应用。
9.根据权利要求8所述的应用,其特征在于,所述煤工尘肺的病症为:呼吸困难、咳嗽、咳痰。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311647320.1A CN117695351B (zh) | 2023-12-04 | 2023-12-04 | 一种治疗煤工尘肺的中药组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311647320.1A CN117695351B (zh) | 2023-12-04 | 2023-12-04 | 一种治疗煤工尘肺的中药组合物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117695351A CN117695351A (zh) | 2024-03-15 |
CN117695351B true CN117695351B (zh) | 2024-05-28 |
Family
ID=90143392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311647320.1A Active CN117695351B (zh) | 2023-12-04 | 2023-12-04 | 一种治疗煤工尘肺的中药组合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117695351B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103191371A (zh) * | 2013-04-12 | 2013-07-10 | 天津中医药大学第二附属医院 | 一种预防/治疗呼吸系统疾病的药物组合物及其用途 |
-
2023
- 2023-12-04 CN CN202311647320.1A patent/CN117695351B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103191371A (zh) * | 2013-04-12 | 2013-07-10 | 天津中医药大学第二附属医院 | 一种预防/治疗呼吸系统疾病的药物组合物及其用途 |
Non-Patent Citations (1)
Title |
---|
周平安诊治肺间质纤维化的经验;付小芳等;《北京中医药》;20100225;第29卷(第2期);99-100 * |
Also Published As
Publication number | Publication date |
---|---|
CN117695351A (zh) | 2024-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102698122A (zh) | 用于治疗牙周炎的中药、制备方法、牙膏和给药方式 | |
CN118434431A (zh) | 一种中药组合物及其制备方法与应用 | |
CN1586552A (zh) | 一种治疗婴幼儿热型咳嗽的外贴膏及制备方法 | |
CN113730535A (zh) | 一种治疗肺癌的中药组合物及其中药制剂制备方法和用途 | |
CN105055950A (zh) | 一种治疗复发性口腔溃疡的中药制剂及其制备方法 | |
CN104784622B (zh) | 用于治疗慢性牙周炎的中药制剂其制备方法 | |
CN117695351B (zh) | 一种治疗煤工尘肺的中药组合物及制备方法 | |
CN101190306B (zh) | 一种具有补气健脾功能的复方组合物及其制备方法和用途 | |
CN103041030A (zh) | 一种治疗大头瘟的药物组合物及其制备方法和用途 | |
CN103028047B (zh) | 一种治疗慢性咽喉炎的中成药 | |
CN113101331B (zh) | 一种百里香药茶及其制备方法和应用 | |
CN115486488A (zh) | 一种用于普通食品的茶饮组合物及其应用 | |
CN103520367B (zh) | 一种治疗荨麻疹的药物组合物及其制备方法和用途 | |
CN113827652A (zh) | 一种治疗偏头痛的中药组合物及其制备方法和应用 | |
CN105250968A (zh) | 一种治疗哮喘的中药制剂 | |
CN114470046B (zh) | 一种治疗过敏性哮喘的中药组方及其应用 | |
CN104491318A (zh) | 一种治疗哮喘的中药制剂及其制备方法 | |
CN114949136B (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法和应用 | |
CN110302337B (zh) | 一种治疗口腔牙周及黏膜类疾病的药物组合物及制备方法和用途 | |
CN115252729B (zh) | 一种治疗糖尿病的中药组合物及其应用 | |
CN103341095A (zh) | 一种慢性肾衰竭用灌肠液 | |
CN112138105B (zh) | 一种治疗支气管扩张症肺脾气虚、痰湿阻肺证的中药组合物及其应用 | |
CN111329927B (zh) | 一种治疗女性特发性水肿的中药 | |
CN104547810A (zh) | 一种治疗肺癌的中药制剂 | |
CN105232962A (zh) | 一种用于制备治疗皮肤病的药物的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |